$NEXI
NexImmune, Inc.

2023 Q4 Form 10-Q Financial Statement

#000153821023000033 Filed on November 17, 2023

View on sec.gov

Income Statement

Concept 2023 Q4 2023 Q3
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $2.405M $3.990M
YoY Change -33.62% 4.64%
% of Gross Profit
Research & Development $2.272M $6.006M
YoY Change -83.32% -46.07%
% of Gross Profit
Depreciation & Amortization $228.5K $266.5K
YoY Change -13.47% 2.14%
% of Gross Profit
Operating Expenses $4.677M $9.996M
YoY Change -72.88% -32.72%
Operating Profit -$9.996M
YoY Change -32.72%
Interest Expense $45.44K $154.9K
YoY Change -85.81%
% of Operating Profit
Other Income/Expense, Net $63.73K $141.6K
YoY Change 87.61% 11.73%
Pretax Income -$5.359M -$9.854M
YoY Change -68.28% -33.1%
Income Tax $0.00 $0.00
% Of Pretax Income
Net Earnings -$5.359M -$9.854M
YoY Change -68.28% -33.1%
Net Earnings / Revenue
Basic Earnings Per Share -$9.40
Diluted Earnings Per Share -$5.04 -$9.40
COMMON SHARES
Basic Shares Outstanding 1.058M shares 26.08M shares
Diluted Shares Outstanding 1.048M shares

Balance Sheet

Concept 2023 Q4 2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments $3.202M $9.000M
YoY Change -90.76% -80.37%
Cash & Equivalents $3.202M $9.000M
Short-Term Investments $0.00
Other Short-Term Assets $2.199M $72.38K
YoY Change 447.01% 74.87%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $5.401M $10.32M
YoY Change -85.55% -80.15%
LONG-TERM ASSETS
Property, Plant & Equipment $1.400M $3.705M
YoY Change -68.61% -17.78%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $1.793M $0.00
YoY Change 576.82% -100.0%
Total Long-Term Assets $3.193M $4.241M
YoY Change -43.89% -25.25%
TOTAL ASSETS
Total Short-Term Assets $5.401M $10.32M
Total Long-Term Assets $3.193M $4.241M
Total Assets $8.594M $14.56M
YoY Change -80.04% -74.75%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.336M $737.5K
YoY Change -43.79% -41.49%
Accrued Expenses $3.748M $4.965M
YoY Change -49.06% -34.14%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $5.084M $6.205M
YoY Change -50.8% -33.95%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $0.00 $102.8K
YoY Change -100.0% -81.78%
Total Long-Term Liabilities $0.00 $102.8K
YoY Change -100.0% -81.78%
TOTAL LIABILITIES
Total Short-Term Liabilities $5.084M $6.205M
Total Long-Term Liabilities $0.00 $102.8K
Total Liabilities $5.084M $6.308M
YoY Change -52.75% -36.66%
SHAREHOLDERS EQUITY
Retained Earnings -$222.6M -$217.2M
YoY Change 17.03% 25.26%
Common Stock $2.646K $2.645K
YoY Change 1.46% 1.42%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.510M $8.254M
YoY Change
Total Liabilities & Shareholders Equity $8.594M $14.56M
YoY Change -80.04% -74.75%

Cashflow Statement

Concept 2023 Q4 2023 Q3
OPERATING ACTIVITIES
Net Income -$5.359M -$9.854M
YoY Change -68.28% -33.1%
Depreciation, Depletion And Amortization $228.5K $266.5K
YoY Change -13.47% 2.14%
Cash From Operating Activities -$5.833M -$7.288M
YoY Change -47.57% -38.59%
INVESTING ACTIVITIES
Capital Expenditures $0.00 -$1.280K
YoY Change -100.0% -99.77%
Acquisitions
YoY Change
Other Investing Activities $0.00 $4.230K
YoY Change -100.0% -99.97%
Cash From Investing Activities $0.00 $5.510K
YoY Change -100.0% -99.95%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 0.000 0.000
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -5.833M -7.288M
Cash From Investing Activities 0.000 5.510K
Cash From Financing Activities 0.000 0.000
Net Change In Cash -5.833M -7.282M
YoY Change -48.24% -239.61%
FREE CASH FLOW
Cash From Operating Activities -$5.833M -$7.288M
Capital Expenditures $0.00 -$1.280K
Free Cash Flow -$5.833M -$7.286M
YoY Change -48.61% -35.54%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
935144 shares
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1265008 usd
CY2023Q3 us-gaap Assets Current
AssetsCurrent
10320218 usd
CY2023Q3 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
3705418 usd
CY2023Q3 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
536058 usd
CY2023Q3 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
0 usd
CY2023Q3 us-gaap Assets
Assets
14561694 usd
CY2023Q3 us-gaap Accounts Payable Current
AccountsPayableCurrent
737494 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4965374 usd
CY2023Q3 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
501811 usd
CY2023Q3 us-gaap Liabilities Current
LiabilitiesCurrent
6204679 usd
CY2023Q3 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
102827 usd
CY2022Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
425766 usd
CY2023Q3 us-gaap Liabilities
Liabilities
6307506 usd
CY2023Q3 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
usd
CY2023Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2022Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
250000000 shares
CY2023Q3 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1058125 shares
CY2023Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
154900 usd
CY2022Q3 us-gaap Investment Income Interest
InvestmentIncomeInterest
226752 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
652959 usd
us-gaap Investment Income Interest
InvestmentIncomeInterest
344066 usd
CY2023Q3 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-13320 usd
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-121653 usd
CY2022Q3 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
126721 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
620067 usd
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
222413 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9854187 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14729380 usd
us-gaap Net Income Loss
NetIncomeLoss
-26985768 usd
us-gaap Net Income Loss
NetIncomeLoss
-45613174 usd
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.09
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.09
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
0
nexi Share Based Compensation Arrangement By Share Based Payment Award Options Cancelled In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsCancelledInPeriod
26224 shares
nexi Share Based Compensation Arrangements By Share Based Payment Award Options Cancelled In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsCancelledInPeriodWeightedAverageExercisePrice
329.42
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
17032 shares
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
74.45
CY2023Q3 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1058125 shares
CY2022Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
1043083 shares
CY2022Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
1043083 shares
CY2023Q3 us-gaap Common Stock Value
CommonStockValue
2645 usd
CY2022Q4 us-gaap Common Stock Value
CommonStockValue
2608 usd
CY2023Q3 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
225486965 usd
CY2022Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
222547530 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217235422 usd
CY2022Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-190249654 usd
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8254188 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32300484 usd
CY2023Q3 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
14561694 usd
CY2022Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
43059824 usd
CY2023Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
6005987 usd
CY2022Q3 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
11136500 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
17010369 usd
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
33422862 usd
CY2023Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3989780 usd
CY2022Q3 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
3719601 usd
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
10595466 usd
CY2023Q3 us-gaap Operating Expenses
OperatingExpenses
9995767 usd
us-gaap Operating Expenses
OperatingExpenses
45835587 usd
CY2022Q3 us-gaap Operating Income Loss
OperatingIncomeLoss
-14856101 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-27605835 usd
us-gaap Operating Income Loss
OperatingIncomeLoss
-45835587 usd
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.40
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.40
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-48.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-48.78
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1044733 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1044733 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
935144 shares
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9854187 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14729380 usd
us-gaap Net Income Loss
NetIncomeLoss
-26985768 usd
us-gaap Net Income Loss
NetIncomeLoss
-45613174 usd
CY2023Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9335 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
0 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3012 usd
CY2023Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9854187 usd
CY2022Q3 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-14720045 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-26985768 usd
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-45616186 usd
CY2023Q3 us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
0 usd
CY2023Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1105893 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9854187 usd
CY2023Q3 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
76 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8254188 usd
CY2022Q3 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5145409 usd
CY2022Q3 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1437488 usd
CY2022Q3 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
9335 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14729380 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
47715533 usd
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
32300484 usd
us-gaap Restricted Stock Value Shares Issued Net Of Tax Withholdings
RestrictedStockValueSharesIssuedNetOfTaxWithholdings
usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
2939472 usd
us-gaap Net Income Loss
NetIncomeLoss
-26985768 usd
us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
76 shares
CY2023Q3 us-gaap Stockholders Equity
StockholdersEquity
8254188 usd
CY2021Q4 us-gaap Stockholders Equity
StockholdersEquity
83760667 usd
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5145409 usd
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
33255 usd
nexi Stock Issued During Period Value Cashless Common Stock Exercised
StockIssuedDuringPeriodValueCashlessCommonStockExercised
0 usd
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
4392388 usd
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-3012 usd
us-gaap Net Income Loss
NetIncomeLoss
-45613174 usd
CY2022Q3 us-gaap Stockholders Equity
StockholdersEquity
47715533 usd
us-gaap Net Income Loss
NetIncomeLoss
-45613174 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
796464 usd
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
730701 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
0 usd
us-gaap Gain Loss On Investments
GainLossOnInvestments
1131 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
3691 usd
us-gaap Gain Loss On Disposition Of Assets1
GainLossOnDispositionOfAssets1
-94803 usd
us-gaap Share Based Compensation
ShareBasedCompensation
2939472 usd
us-gaap Share Based Compensation
ShareBasedCompensation
4392388 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
430974 usd
us-gaap Operating Lease Right Of Use Asset Amortization Expense
OperatingLeaseRightOfUseAssetAmortizationExpense
372110 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-1681376 usd
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1387936 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1639881 usd
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
264716 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-2396409 usd
us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
1445551 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-420175 usd
us-gaap Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-363997 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-25597638 usd
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-40065969 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48720 usd
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
1031153 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
4228 usd
us-gaap Proceeds From Sale Of Machinery And Equipment
ProceedsFromSaleOfMachineryAndEquipment
0 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
0 usd
us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
21509940 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
0 usd
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
71500000 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
0 usd
us-gaap Proceeds From Sale Of Available For Sale Securities Debt
ProceedsFromSaleOfAvailableForSaleSecuritiesDebt
1500000 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-44492 usd
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
50458907 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0 usd
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
5145409 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0 usd
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
33255 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 usd
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5178664 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-25642130 usd
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
15571602 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34697340 usd
CY2021Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30393852 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9055210 usd
CY2022Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45965454 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
0 usd
us-gaap Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
5478 usd
CY2023Q3 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-217200000 usd
CY2023Q3 us-gaap Debt Longterm And Shortterm Combined Amount
DebtLongtermAndShorttermCombinedAmount
0 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9000000.0 usd
CY2023Q3 us-gaap Cash
Cash
874470 usd
CY2022Q4 us-gaap Cash
Cash
2940733 usd
CY2023Q3 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
9000210 usd
CY2022Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
34642340 usd
CY2023Q3 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
9055210 usd
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
34697340 usd
CY2023Q3 nexi Prepaid Research And Development Expenses
PrepaidResearchAndDevelopmentExpenses
457044 usd
CY2023Q3 nexi Prepaid Maintenance Agreements
PrepaidMaintenanceAgreements
87991 usd
CY2023Q3 us-gaap Prepaid Insurance
PrepaidInsurance
512430 usd
CY2023Q3 us-gaap Other Prepaid Expense Current
OtherPrepaidExpenseCurrent
96155 usd
CY2023Q3 us-gaap Interest Receivable
InterestReceivable
39009 usd
CY2022Q4 us-gaap Interest Receivable
InterestReceivable
74467 usd
CY2023Q3 us-gaap Other Assets Current
OtherAssetsCurrent
72379 usd
CY2023Q3 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1265008 usd
CY2022Q3 us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
300000 usd
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
800000 usd
us-gaap Cost Of Goods And Services Sold Depreciation And Amortization
CostOfGoodsAndServicesSoldDepreciationAndAmortization
700000 usd
CY2023Q3 nexi Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3066740 usd
CY2022Q4 nexi Accrued Research And Development Costs Current
AccruedResearchAndDevelopmentCostsCurrent
3210794 usd
CY2023Q3 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
1566998 usd
CY2022Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
3855797 usd
CY2023Q3 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
308536 usd
CY2022Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
267383 usd
CY2023Q3 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23100 usd
CY2022Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
23179 usd
CY2023Q3 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
4965374 usd
CY2022Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
7357153 usd
CY2023Q3 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
25000 usd
CY2022Q4 us-gaap Accrued Royalties Current And Noncurrent
AccruedRoyaltiesCurrentAndNoncurrent
50000 usd
CY2023Q3 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2022Q4 us-gaap Loss Contingency Accrual At Carrying Value
LossContingencyAccrualAtCarryingValue
0 usd
CY2022Q4 nexi Restructuring And Related Cost Expected Number Of Positions Eliminated Period Percent
RestructuringAndRelatedCostExpectedNumberOfPositionsEliminatedPeriodPercent
0.30
CY2022Q4 nexi Restructuring And Related Cost Number Of Positions Before Eliminations
RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations
74 employee
CY2022Q4 nexi Restructuring And Related Cost Number Of Positions After Eliminations
RestructuringAndRelatedCostNumberOfPositionsAfterEliminations
50 employee
CY2022Q4 us-gaap Restructuring And Related Cost Expected Cost1
RestructuringAndRelatedCostExpectedCost1
700000 usd
CY2023Q3 nexi Restructuring And Related Cost Number Of Positions Before Eliminations
RestructuringAndRelatedCostNumberOfPositionsBeforeEliminations
44 employee
CY2023Q3 nexi Restructuring And Related Cost Number Of Positions After Eliminations
RestructuringAndRelatedCostNumberOfPositionsAfterEliminations
22 employee
CY2023Q3 us-gaap Restructuring And Related Cost Cost Incurred To Date1
RestructuringAndRelatedCostCostIncurredToDate1
2000000.0 usd
CY2022 us-gaap Restructuring Charges
RestructuringCharges
500000 usd
CY2022Q4 us-gaap Restructuring Reserve
RestructuringReserve
382389 usd
us-gaap Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
9.44
us-gaap Restructuring Charges
RestructuringCharges
2105521 usd
us-gaap Payments For Restructuring
PaymentsForRestructuring
1877538 usd
CY2023Q3 us-gaap Restructuring Reserve
RestructuringReserve
610372 usd
CY2023Q1 us-gaap Share Price
SharePrice
0.41
CY2023Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1105893 usd
CY2022Q3 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1437488 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2939472 usd
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
4392388 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
400000 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Accelerated Compensation Cost
ShareBasedCompensationArrangementByShareBasedPaymentAwardAcceleratedCompensationCost
400000 usd
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
158620 shares
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
184.51
CY2022 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P8Y
CY2022Q4 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
46644 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
162008 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
26.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
P7Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
162008 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
26.62
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1
P7Y
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue
0 usd
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
103734 shares
CY2023Q3 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
34.13
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1
P5Y7M6D
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1
0 usd
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Number Of Shares
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedNumberOfShares
58277 shares
CY2023Q3 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Weighted Average Grant Date Fair Value
SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValue
13.26
nexi Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Weighted Average Remaining Contractual Term1
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingWeightedAverageRemainingContractualTerm1
P9Y1M6D
CY2023Q3 nexi Share Based Compensation Arrangement By Share Based Payment Award Options Non Vested Outstanding Aggregate Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsNonVestedOutstandingAggregateIntrinsicValue
0 usd
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
7.17
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
61.00
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.902
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.937
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum
0.786
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum
0.826
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.034
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.042
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum
0.015
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum
0.036
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
0 shares
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000 usd
CY2023Q3 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
2800000 usd
CY2023Q3 us-gaap Net Income Loss
NetIncomeLoss
-9854187 usd
CY2022Q3 us-gaap Net Income Loss
NetIncomeLoss
-14729380 usd
us-gaap Net Income Loss
NetIncomeLoss
-26985768 usd
us-gaap Net Income Loss
NetIncomeLoss
-45613174 usd
CY2023Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-9.40
CY2023Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-9.40
CY2022Q3 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-15.09
CY2022Q3 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-15.09
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-25.83
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-25.83
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-48.78
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-48.78
CY2023Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1047871 shares
CY2023Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1047871 shares
CY2022Q3 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
976413 shares
CY2022Q3 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
976413 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
1044733 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
1044733 shares
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
935144 shares
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
935144 shares
CY2023Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
199286 shares
CY2022Q3 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
158667 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
199286 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
158667 shares
CY2022Q1 nexi Related Party Transaction Term
RelatedPartyTransactionTerm
P2Y
CY2023Q3 us-gaap Related Party Transaction Amounts Of Transaction
RelatedPartyTransactionAmountsOfTransaction
200000 usd
CY2023Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
CY2022Q3 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0 usd
us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2022Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0
CY2023Q3 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
0

Files In Submission

Name View Source Status
nexi-20230930_def.xml Edgar Link unprocessable
0001538210-23-000033-index-headers.html Edgar Link pending
0001538210-23-000033-index.html Edgar Link pending
0001538210-23-000033.txt Edgar Link pending
0001538210-23-000033-xbrl.zip Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
nexi-20230930.htm Edgar Link pending
nexi-20230930.xsd Edgar Link pending
nexi-20230930xexx311.htm Edgar Link pending
nexi-20230930xexx312.htm Edgar Link pending
nexi-20230930xexx321.htm Edgar Link pending
nexi-20230930xexx322.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
nexi-20230930_cal.xml Edgar Link unprocessable
nexi-20230930_lab.xml Edgar Link unprocessable
nexi-20230930_htm.xml Edgar Link completed
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending
nexi-20230930_pre.xml Edgar Link unprocessable